Related Experiment Video
Updated: Oct 4, 2025
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
Recurrent Drug-Induced Hypersensitivity Syndrome Following Bortezomib for Multiple Myeloma
Austin B Ambur1, Rajiv Nathoo1
1Dermatology, Advanced Dermatology and Cosmetic Surgery, Oviedo, USA.
Cureus
|February 10, 2022
Summary
Drug-induced hypersensitivity syndrome (DIHS) is a severe reaction to medications. This case highlights bortezomib as a rare cause of recurrent DIHS in multiple myeloma patients, emphasizing long-term management challenges.
Area of Science:
- Pharmacology
- Immunology
- Oncology
Background:
- Drug-induced hypersensitivity syndrome (DIHS) is a severe, delayed hypersensitivity reaction.
- Commonly implicated drugs include anticonvulsants, sulfonamides, minocycline, dapsone, and allopurinol.
- Bortezomib, a proteasome inhibitor, is rarely linked to hypersensitivity reactions.
Observation:
- A case of recurrent DIHS secondary to bortezomib in a multiple myeloma patient is presented.
- This highlights bortezomib as a unique mediator of DIHS.
- The patient experienced a relapse of the syndrome, underscoring management difficulties.
Findings:
- Bortezomib can cause recurrent drug-induced hypersensitivity syndrome.
- DIHS management in patients on bortezomib presents unique challenges.
- Delayed hypersensitivity reactions require careful monitoring and long-term strategies.
Implications:
- Clinicians should consider bortezomib as a potential cause of DIHS, especially in multiple myeloma patients.
- Awareness of this rare association is crucial for timely diagnosis and intervention.
- Effective long-term management strategies are needed to prevent recurrent DIHS and improve patient outcomes.
Keywords:
bortezomibdress syndromedrug-induced hypersensitivity syndromemultiple myelomaproteasome inhibitorsMore Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.4K
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
13.4K
Related Concept Videos
01:20Desensitization and Tachyphylaxis
2.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.4K
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
22
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
22
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
8
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
8
01:27Allergic Drug Reactions
1.0K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.0K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:30Hypersensitivities
1.2K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
1.2K